Background: Simple, chip and rapid analytical methods are required in biomedical analysis laboratories to support therapeutic drug monitoring units in hospitals. The present work aimed to provide such a method for quantitative determination of carvedilol in plasma samples.
Results: A new, simple, precise and efficient method was developed for the determination of carvedilol in human plasma using a dispersive liquid-liquid microextraction based on solidification of floating organic droplet, followed by spectrofluorimetry method. Some important parameters such as types and volumes of extraction and disperser solvents, pH, salt effect and sample volume were optimized. Under the optimized experimental conditions, the method provided a linear range of 40 to 300 ng ml(-1), with a correlation coefficient of 0.996. The limit of detection, lower limit of quantification and upper limit of quantification were 18, 40 and 300 ng ml(-1), respectively. The found recovery was from 98.2 to 102.2%, the mean intra- and inter-day precisions were 8.3 and 6.4%, respectively. The relative error for accuracy varied from 0.4 to 2.2%. The short-term temperature and freeze-thaw stability studies showed that carvedilol in human plasma was stable for sample preparation and analysis after storage.
Conclusion: The proposed method provided reasonable acceptable results and could be used for therapeutic monitoring of carvedilol.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4155/bio.12.326 | DOI Listing |
J Clin Gastroenterol
November 2024
Departments of Gastroenterology.
Introduction And Objectives: The portal vein pressure higher than 10 mm Hg in patients with hepatic cirrhosis is more likely to have serious complications and poor prognosis. Nonselective receptor blockers (NSBBs) can reduce the portal vein pressure; however, the efficacy and safety of different NSBBs in reducing portal vein pressure were unconsistent. A systematic review and meta-analysis was conducted to evaluate the efficacy and safety of carvedilol versus propranolol in reducing portal vein pressure in this study.
View Article and Find Full Text PDFClin J Am Soc Nephrol
January 2025
Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California.
J Fluoresc
December 2024
Department of Pharmaceutical Chemistry, College of Pharmacy, Shaqra University, Shaqra, 11961, Saudi Arabia.
Hypertension is the predominant risk factor for cardiovascular diseases and mortality. This study presents the first method for the simultaneous analysis of the co-administered antihypertensive drugs, Carvedilol (CAR) and Telmisartan (TEL) using a fast, highly sensitive, environmentally friendly, and cost-effective second derivative synchronous spectrofluorimetric approach. The fluorescence of CAR and TEL was quantified at 243 nm and 274.
View Article and Find Full Text PDFBMJ Open
August 2024
Department of Cardiology, Samsung Medical Center, Seoul, Republic of Korea
Introduction: There is a lack of evidence to support the effectiveness of prolonged β-blocker therapy after stabilisation of patients with acute myocardial infarction (AMI) without heart failure (HF) or left ventricular systolic dysfunction.
Methods And Analysis: The SMart Angioplasty Research Team: DEcision on Medical Therapy in Patients with Coronary Artery DIsease or Structural Heart Disease Undergoing InterventiON (SMART-DECISION) trial is a multicentre, prospective, open-label, randomised, non-inferiority trial designed to determine whether discontinuing β-blocker therapy after ≥1 year of maintenance in stabilised patients after AMI is non-inferior to continuing it. Patients eligible for participation are those without HF or left ventricular systolic dysfunction (ejection fraction >40%) who have been continuing β-blocker therapy for ≥1 year after AMI.
J Diabetes Res
December 2024
Department of Cardiology, The First People's Hospital of Kashi Prefecture, Kashi, China.
This study investigates the impact of a high-sugar environment on H9C2 cardiomyocytes and explores the protective effects of carvedilol in the context of diabetic cardiomyopathy (Dia-CM). Transcriptomic analysis identified 21,655 differentially expressed genes associated with Dia-CM, demonstrating significant separation among samples. H9C2 cardiomyocytes were cultured in a high-sugar environment to simulate Dia-CM conditions.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!